Jochum W - Search Results

1

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M. Diem S, et al. Among authors: jochum w. Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024. Epub 2017 Jul 24. Lung Cancer. 2017. PMID: 28838390

2

Prognostic significance of nuclear DNA content and proliferative activity in renal cell carcinomas. A clinicopathologic study of 58 patients using mitotic count, MIB-1 staining, and DNA cytophotometry.

Jochum W, Schröder S, al-Taha R, August C, Gross AJ, Berger J, Padberg BC. Jochum W, et al. Cancer. 1996 Feb 1;77(3):514-21. doi: 10.1002/(SICI)1097-0142(19960201)77:3<514::AID-CNCR13>3.0.CO;2-7. Cancer. 1996. PMID: 8630959

3

Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.

V Laffert M, Warth A, Penzel R, Schirmacher P, Jonigk D, Kreipe H, Schildhaus HU, Merkelbach-Bruse S, Büttner R, Reu S, Kerler R, Jung A, Kirchner T, Wölfel C, Petersen I, Rodriguez R, Jochum W, Bartsch H, Fisseler-Eckhoff A, Berg E, Lenze D, Dietel M, Hummel M. V Laffert M, et al. Among authors: jochum w. Lung Cancer. 2013 Aug;81(2):200-6. doi: 10.1016/j.lungcan.2013.04.015. Epub 2013 May 10. Lung Cancer. 2013. PMID: 23669200

4

Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.

Savic S, Diebold J, Zimmermann AK, Jochum W, Baschiera B, Grieshaber S, Tornillo L, Bisig B, Kerr K, Bubendorf L. Savic S, et al. Among authors: jochum w. Lung Cancer. 2015 Aug;89(2):104-9. doi: 10.1016/j.lungcan.2015.05.012. Epub 2015 May 21. Lung Cancer. 2015. PMID: 26056079

5

Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung.

Reichegger H, Jochum W, Förbs D, Hader C, Früh M. Reichegger H, et al. Among authors: jochum w. Oncol Res Treat. 2016;39(7-8):461-3. doi: 10.1159/000446759. Epub 2016 Jun 15. Oncol Res Treat. 2016. PMID: 27486808

6

Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Früh M, Flatz L. Hasan Ali O, et al. Among authors: jochum w. Oncoimmunology. 2016 Sep 19;5(11):e1231292. doi: 10.1080/2162402X.2016.1231292. eCollection 2016. Oncoimmunology. 2016. PMID: 27999741 Free PMC article.

7

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).

Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M. Schmid S, et al. Among authors: jochum w. J Thorac Oncol. 2017 Apr;12(4):681-688. doi: 10.1016/j.jtho.2016.12.003. Epub 2016 Dec 19. J Thorac Oncol. 2017. PMID: 28007627 Free article.

8

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.

Ess SM, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M. Ess SM, et al. Among authors: jochum w. Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12721. Epub 2017 May 30. Eur J Cancer Care (Engl). 2017. PMID: 28557060

9

Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with primary surgery.

Broglie MA, Stoeckli SJ, Sauter R, Pasche P, Reinhard A, de Leval L, Huber GF, Pezier TF, Soltermann A, Giger R, Arnold A, Dettmer M, Arnoux A, Müller M, Spreitzer S, Lang F, Lutchmaya M, Stauffer E, Espeli V, Martucci F, Bongiovanni M, Foerbs D, Jochum W. Broglie MA, et al. Among authors: jochum w. Head Neck. 2017 Oct;39(10):2004-2015. doi: 10.1002/hed.24865. Epub 2017 Jul 10. Head Neck. 2017. PMID: 28691255

10

Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.

Diem S, Hasan Ali O, Ackermann CJ, Bomze D, Koelzer VH, Jochum W, Speiser DE, Mertz KD, Flatz L. Diem S, et al. Among authors: jochum w. Cancer Immunol Immunother. 2018 Jan;67(1):39-45. doi: 10.1007/s00262-017-2061-4. Epub 2017 Sep 11. Cancer Immunol Immunother. 2018. PMID: 28894934 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

191 results

Search Page